Fortress Biotech (NASDAQ:FBIO) Downgraded to “Sell” at lowered shares of Fortress Biotech (NASDAQ:FBIOFree Report) from a hold rating to a sell rating in a research report sent to investors on Monday.

FBIO has been the topic of several other research reports. Roth Mkm reaffirmed a buy rating and set a $10.00 price target on shares of Fortress Biotech in a research report on Thursday, May 16th. Alliance Global Partners began coverage on shares of Fortress Biotech in a research report on Tuesday, March 19th. They set a buy rating and a $5.00 target price on the stock.

View Our Latest Analysis on FBIO

Fortress Biotech Stock Up 2.7 %

Fortress Biotech stock opened at $1.89 on Monday. The company has a 50 day moving average of $1.83 and a 200-day moving average of $2.09. The company has a quick ratio of 1.21, a current ratio of 1.33 and a debt-to-equity ratio of 38.42. Fortress Biotech has a twelve month low of $1.24 and a twelve month high of $10.65. The stock has a market capitalization of $37.65 million, a PE ratio of -0.31 and a beta of 1.68.

Fortress Biotech (NASDAQ:FBIOGet Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.00. Fortress Biotech had a negative return on equity of 770.86% and a negative net margin of 69.13%. The company had revenue of $13.03 million during the quarter, compared to analysts’ expectations of $14.33 million. On average, equities research analysts anticipate that Fortress Biotech will post -5.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Fortress Biotech

Institutional investors have recently modified their holdings of the business. Gladstone Institutional Advisory LLC bought a new stake in shares of Fortress Biotech during the 4th quarter valued at approximately $36,000. Virtu Financial LLC bought a new position in Fortress Biotech during the 1st quarter worth $31,000. PFG Investments LLC acquired a new position in shares of Fortress Biotech in the first quarter worth approximately $33,000. Wealth Management Partners LLC acquired a new position in shares of Fortress Biotech in the 4th quarter worth approximately $60,000. Finally, Choreo LLC acquired a new position in Fortress Biotech in the fourth quarter valued at $109,000. Institutional investors and hedge funds own 96.51% of the company’s stock.

Fortress Biotech Company Profile

(Get Free Report)

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.

See Also

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with's FREE daily email newsletter.